May 2024
Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial
Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation
Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data
J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.
Biopharma Downsizing Trends 2024: Major Companies Adjusting Workforce
Biopharma, layoffs, downsizing, workforce reduction, Evotec, Lyra Therapeutics, Takeda Pharmaceuticals, industry trends, 2024
Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates
Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.
AstraZeneca Acquires Option for SixPeaks: A Potential Breakthrough in Obesity Biotechnology
AstraZeneca, SixPeaks, Versant Ventures, obesity, biotechnology, acquisition, option, breakthrough.
AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody
AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
BIO Undergoes Transformative Restructuring for Future Growth
BIO, lobbying group, reorganization, restructuring, layoffs, future growth, transformation, biotechnology industry.
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China
AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.
AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing
AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.